Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness
Open Access
- 27 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogenesis
- Vol. 10 (2), 1-18
- https://doi.org/10.1038/s41389-021-00308-z
Abstract
Locally advanced oral squamous cell carcinoma (OSCC) requires multimodal therapy, including surgery and concurrent chemoradiotherapy (CCRT). CCRT-resistant and recurrent cancer has a poor prognosis. We investigated the effects of Bruton’s tyrosine kinase (BTK) on CCRT-resistant OSCC tissues. The effect of ibrutinib, a first-in-class BTK inhibitor, was tested on stem cell-like OSCC tumorspheres. A tissue array was constructed using tissue samples from 70 patients with OSCC. Human OSCC cell lines, SAS, TW2.6 and HSC-3, were examined. Wound healing, Matrigel invasion, and tumorsphere formation assays, as well as immunofluorescence analysis and flow cytometry, were used to investigate the effects of BTK knockdown (shBTK), ibrutinib, cisplatin, and ibrutinib/cisplatin combination on OSCC cells. We demonstrated that BTK was aberrantly highly expressed in the clinical CCRT-resistant OSCC tissue array, which resulted in poor overall survival in our local Tri-Service General Hospital and freely accessible TCGA OSCC cohorts. shBTK significantly downregulated the stemness markers Nanog, CD133, T cell immunoglobulin-3 (TIM-3), and Krüppel-like factor 4 (KLF4) in SAS tumorspheres and attenuated OSCC cell migration and colony formation. Ibrutinib reduced the number of aldehyde dehydrogenase (ALDH)-rich OSCC cells and reduced tumorsphere formation, migration, and invasion in a dose-dependent manner. Compared with ibrutinib or cisplatin monotherapy, the ibrutinib/cisplatin combination significantly reduced the formation of ALDH + OSCC tumorspheres and enhanced apoptosis. These results demonstrate that ibrutinib effectively inhibits the CSCs-like phenotype of OSCC cells through dysregulation of BTK/CD133 signaling. The ibrutinib/cisplatin combination may be considered for future clinical use.Keywords
Funding Information
- Ministry of Health and Welfare (MOST 108-2314-B-016-008-MY2)
This publication has 62 references indexed in Scilit:
- Neutrophil cell surface receptors and their intracellular signal transduction pathwaysInternational Immunopharmacology, 2013
- A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosisGenes, Chromosomes and Cancer, 2013
- Improved outcomes in buccal squamous cell carcinomaHead & Neck, 2012
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Two stem cell markers, ATP‐binding cassette, G2 subfamily (ABCG2) and BMI‐1, predict the transformation of oral leukoplakia to cancerCancer, 2011
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour siteRadiotherapy and Oncology, 2011
- Determination of Somatic and Cancer Stem Cell Self-Renewing Symmetric Division Rate Using Sphere AssaysPLOS ONE, 2011
- Characterization of Side Populations in HNSCC: Highly Invasive, Chemoresistant and Abnormal Wnt SignalingPLOS ONE, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Mutations in Btk in Patients with Presumed X-Linked AgammaglobulinemiaAmerican Journal of Human Genetics, 1998